Local delivery of checkpoints antibodies

References

• Klevorn LE, Teague RM. Adapting Cancer Immunotherapy Models for the Real World. Trends Immunol 2016; 37:354-63; PMID:27105824
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348:56-61
   PubMed Web of Science ®Google Scholar
• Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin. Invest 2015; 125:3384-91; PMID:26325035; http://dx.doi.org/10.1172/JCI80011
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015; 14:561-84; PMID:26228759; http://dx.doi.org/10.1038/nrd4591
   PubMed Web of Science ®Google Scholar
• Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H. Neoantigen landscape dynamics during human melanoma–T cell interactions. Nature 2016; 536:91-5; PMID:27350335
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 2016; 8:328rv4; PMID:26936508; http://dx.doi.org/10.1126/scitranslmed.aad7118
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2015; 372:320-30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette G. P, Meyer N, Giguere JK, Agarwala SS, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006-17; PMID:25891304; http://dx.doi.org/10.1056/NEJMoa1414428
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387:1909-0
   PubMed Web of Science ®Google Scholar
• Mellati M, Eaton KD, Brooks-Worrell BM, Hagopian WA, Martins R, Palmer JP, Hirsch IB. Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes. Diabetes Care 2015; 38:e137-8; PMID:26116720; http://dx.doi.org/10.2337/dc15-0889
   PubMed Web of Science ®Google Scholar
• Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016; 13:473-86; PMID:27141885
   PubMed Web of Science ®Google Scholar
• Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 2015; 26:2375-91 mdv383; PMID:26371282
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Hodi FS. Melanoma in 2015: Immune-checkpoint blockade - durable cancer control. Nat Rev Clin Oncol 2016; 13:77-8; http://dx.doi.org/10.1038/nrclinonc.2015.237
   PubMed Web of Science ®Google Scholar
• Jeanbart L, Swartz MA. Engineering opportunities in cancer immunotherapy. Proc Natl Acad Sci USA 2015; 112:14467-72; http://dx.doi.org/10.1073/pnas.1508516112
   PubMed Web of Science ®Google Scholar
• Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca I. G, Chamaillard M, Kroemer G. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and-Extrinsic Factors. Immunity 2016; 44:1255-69
   PubMed Web of Science ®Google Scholar
• Wang C, Ye Y, Hochu GM, Sadeghifar H, Gu Z. Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. Nano Lett 2016; 16:2334-40; PMID:26999507; http://dx.doi.org/10.1021/acs.nanolett.5b05030
   PubMed Web of Science ®Google Scholar
• Quinn HL, Kearney MC, Courtenay AJ, McCrudden MTC, Donnelly RF. The role of microneedles for drug and vaccine delivery. Expert Opin Drug Deliv 2014; 11:1769-80; PMID:25020088; http://dx.doi.org/10.1517/17425247.2014.938635
   PubMed Web of Science ®Google Scholar
• Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012; 64:1547-68; PMID:22575858; http://dx.doi.org/10.1016/j.addr.2012.04.005
   PubMed Web of Science ®Google Scholar
• Ye Y, Yu J, Wang C, Nguyen NY, Walker GM, Buse JB, Gu Z. Microneedles integrated with pancreatic cells and synthetic glucose-signal amplifiers for smart insulin delivery. Adv Mater 2016; 28:3115-21; PMID:26928976; http://dx.doi.org/10.1002/adma.201506025
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang Y, Ye Y, DiSanto R, Sun W, Ranson D, Ligler FS, Buse JB, Gu Z. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proc Natl Acad Sci USA 2015; 112:8260-5; PMID:26100900; http://dx.doi.org/10.1073/pnas.1505405112
   PubMed Web of Science ®Google Scholar
• Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, Murthy N, Compans RW, Skountzou I, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010; 16:915-20; PMID:20639891; http://dx.doi.org/10.1038/nm.2182
   PubMed Web of Science ®Google Scholar
• Kines RC, Zarnitsyn V, Johnson TR, Pang YYS, Corbett KS, Nicewonger JD, Gangopadhyay A, Chen M, Liu J, Prausnitz MR, et al. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles. Plos One 2015; 10:e0120797; PMID:25785935
   PubMed Web of Science ®Google Scholar
• Minn AJ, Wherry EJ. Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. Cell 2016; 165:272-5
   PubMed Web of Science ®Google Scholar
• Wang C, Sun W, Wright G, Wang A, Gu Z. Inflammation-triggered cancer immunotherapy by programmed delivery of CpG and Anti-PD1 antibody. Adv Mater 2016
   Web of Science ®Google Scholar
• Sun WJ, Gu Z. Engineering DNA scaffolds for delivery of anticancer therapeutics. Biomaterials Sci 2015; 3:1018-24; http://dx.doi.org/10.1039/C4BM00459K
   PubMed Web of Science ®Google Scholar
• Sun W, Ji W, Hall JM, Hu Q, Wang C, Beisel CL, Gu Z. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew Chem Int Ed 2015; 54:12029-33; http://dx.doi.org/10.1002/anie.201506030
   PubMed Web of Science ®Google Scholar
• Sun W, Jiang T, Lu Y, Reiff M, Mo R, Gu Z. Cocoon-like self-degradable DNA nanoclew for anticancer drug delivery. J Am Chem Soc 2014; 136:14722-5; PMID:25336272; http://dx.doi.org/10.1021/ja5088024
   PubMed Web of Science ®Google Scholar
• Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy. Trends Cancer 2016; 2:286-94
   PubMed Web of Science ®Google Scholar
• Hu QY, Sun WJ, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev 2016; 98:19-34; PMID:26546751; http://dx.doi.org/10.1016/j.addr.2015.10.022
   PubMed Web of Science ®Google Scholar
• Goldberg MS. Immunoengineering: how nanotechnology can enhance cancer immunotherapy. Cell 2015; 161:201-4
   PubMed Web of Science ®Google Scholar
• Gu L, Mooney DJ. Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. Nat Rev Cancer 2016; 16:56-66; PMID:26694936; http://dx.doi.org/10.1038/nrc.2015.3
   PubMed Web of Science ®Google Scholar